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EDITORIAL

Hepatology and Nephrology: Nimbus

O

ur two Guest Editors, Jay Koyner and Michael Heung
bring forth the ever-emerging issue of concurrent
liver and kidney disease and those individuals with acute
or chronically impaired hepatic function who develop kidney dysfunction acutely or chronically. They note that
increasingly nephrologists have specialized in areas
outside their usual work, for example, the onconephrologist. Furthermore, they discuss the nascent subspecialist, the hepato-nephrologist.
Liver disease now hangs over kidney disease like a
nimbus cloud, and it seems to be raining liver disease
these days. My opinion may reﬂect the environment at
which I work, an institution that performs liver and kidney transplants and that has a large CKD clinic situated
beside a hepatology clinic. Nephrologists are needed
and asked to participate in the complex care of hospitalized patients with advanced liver disease. Because of
enhanced care of critically ill patients with hepatic failure,
more such patients are surviving, no doubt partly because
of the contribution of nephrologists who purvey various
forms of kidney replacement therapy, which is frequently
required in these circumstances.
Liver transplantation has grown substantially in the
past 2 decades and is lifesaving for pediatric patients
with congenital disorders that eventuate in cirrhosis, adolescents and young adults with acute drug toxicities,
and adults with progressive liver disorders including
nonalcoholic steatohepatitis. As liver transplantation
has burgeoned, more patients now develop kidney disease enroute to liver transplantation or advanced medical therapy. As a case-in-point, the increasing disease
frequency of hepatitis C virus stabilized by 2002 because
of advances in therapy, after having been an underlying
or contributory cause of mortality for nearly the previous
2 decades. The greater survivorship has translated to
more CKD in hepatitis C virus (HCV)-afﬂicted individuals.1 Patients with coincident liver and kidney disease
frequently require liver transplantation and possibly kidney transplantation, singly or simultaneously. This latter
scenario is thoroughly discussed within this journal
issue. Liver patients are also referred to nephrologists
as outpatients for acute or chronic kidney dysfunction,
and this is our point of emphasis. For some, renal consultation of liver patients with acute kidney injury (AKI)

and/or CKD is uncommon, and for others, a nearly daily
occurrence.
Confronted by liver disease, a patient with an elevated
serum creatinine ushers forth several and immediate
questions. Is AKI or CKD present? What diagnostic and
prognostic factors are present? Which treatments will be
of beneﬁt? The classical paradigm was that of underﬁlling
of the circulatory volume attributable to splanchnic arterial vasodilation,2 an ineffective circulatory volume that
provided inadequate kidney perfusion with secondary
hyperaldosteronism and hypokalemia. Although excessive aldosterone-mediated potassium secretion conspires
with poor intake of this mineral, the contribution of
elevated plasma bile acid inactivation of 11-b-hydroxysteroid dehydrogenase type 2 must be considered as well.3
These hemodynamic alterations may conspire with an
associated depression of cardiac function, a described
yet poorly recognized subterfuge that persists even after
normalization of afterload.2 An abdominal compartment
syndrome with attendant elevation of kidney venous
pressure may further attenuate kidney function.
This situation represented the extreme form of type 2
hepatorenal syndrome (HRS) and was associated with a
high rate of mortality. The consequences of exaggerated
sympathetic nervous system activation and impaired
baroreceptor stimulation and hepatic osmoreceptor activation by hypo-osmolality4 led to sodium retention with
a low fractional sodium excretion (FENa) but disproportionate water reabsorption from elaboration of arginine
vasopressin and hyponatremia. In extreme circumstances,
a distal renal tubular acidosis-like picture emerged
because of hyperabsorption of sodium with impaired ammoniagenesis. Volume resuscitation, often with albumin
as colloid, was frequently efﬁcacious but often only on a
limited and temporal basis. The addition of terlipressin
may produce a greater salutary response, but the refractoriness of type 2 HRS limits its utility.
Type 1 HRS responds more favorably to this agent and
represents a form of AKI. There is often a precipitating event
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in type 1 HRS, such as acute alcoholic hepatitis, bacterial
infection, gastrointestinal blood loss of signiﬁcant degree,
or another cause for rapid reduction of effective circulatory
volume. Poor survival measured in days to weeks attends
type 1 HRS, and the only deﬁnitive treatment for this catastrophic disorder is orthotopic liver transplantation, often
after temporizing therapies of vasoconstrictor drugs with
octreotide, albumin, and even transjugular intrahepatic portosystemic shunting. Covert hepatoadrenal insufﬁciency
may be present with diminished cortisolemia and should
be considered as a cause of ongoing asthenia.5 Fortunately,
not all forms of AKI in liver disease are as devastating, and
more slowly, toxic forms of liver-kidney syndromes exist
including that from androgenic, anabolic steroid use with
cholestasis, and AKI. This syndrome may occur in approximately 1% of patients treated with methyltesterone, danazol, stanozolol, or oxymetholone.6,7
Molecular adsorption recirculating system (MARS) therapy is used at some centers for end-stage liver disease patients.8 For now, MARS remains as distant as the planet
itself with small trials demonstrating no beneﬁt of this treatment option. In the best possible situation, kidney failure is
transient and rectiﬁable. The most common conditions for
this favorable outcome are overly ambitious diuretic therapy and/or paracentesis. Routinely, 5 to 6 L volumes are
removed from individuals with ascites whose vascular
reﬁll rate is impossible to ascertain by more than an
educated guess. As discussed by Arroyo,9 therapeutic paracentesis even with prophylactic volume expansion by albumin (8 g/L ascites ﬂuid) often results in a transient
improvement in serum creatinine levels for just a day before
its subsequent deterioration by 48 hours post-paracentesis.
Although FENa has differentiated oliguric states into prerenal azotemia vs non-prerenal AKI, this test is fraught with
hazard when AKI occurs in the setting of end-stage liver
disease. No set of commonly accepted diagnostic criteria
serve the nephrologist or hepatologist well in the determination of etiology, which may have profound prognostic
and management implications. In cirrhotic patients, FENa
may distinguish HRS from prerenal azotemia but will not
discriminate between prerenal azotemia and acute tubular
necrosis. In HRS, the FENa was vanishingly small (,0.1%).
However, biomarkers of tubular injury represent a viable
approach to determine etiology, especially when provided
as a panel of markers for individuals with worsening AKI
stage. The conﬁdence of diagnosing acute tubular necrosis
increases 13-fold using a panel of 4 biomarkers vs none.10
So, at what level of serum creatinine or absolute increase
of serum creatinine should one be concerned? (Box) Two
recent studies shed light on this issue. In one, Fagundes
and colleagues11 evaluated 375 consecutive liver disease
patients with acute complications. AKI Stage 1 (AKI-1) patients with serum creatinine less than 1.5 mg/dL had a 90day probability of survival similar to that of patients
without AKI. In contrast, AKI-1 patients with serum creatinine more than 1.5 mg/dL showed signiﬁcantly lower 90day probability of survival than the aforementioned 2
groups. Piano and colleagues12 studied 233 consecutive
patients with ascites. Serum creatinine was measured at
admission (baseline) and daily inhospital. In this investigation, the inhospital mortality of patients with AKI-1 was

Box. Acute Kidney Injury Criteria in Cirrhosis

 Serum creatinine greater than 1.5 mg/dL.
 Identiﬁcation of a cause of kidney disease (acute
tubular necrosis, exposure to nephrotoxin,
volume depletion, CKD).
 Hepatorenal syndrome, type 1 (rapid) or 2
(chronic), determined according to rate of
progression of renal failure.
 Deterioration of renal function with serum creatinine increase of 50% or more from baseline to a
ﬁnal level of 1.5 mg/dL or more.
 Kidney failure associated with bacterial infections, in the absence of septic shock, which may
follow a variable course of rapidity.

Adapted from Arroyo V. Acute kidney injury (AKI) in
cirrhosis: should we change current deﬁnition and
diagnostic criteria of renal failure in cirrhosis?
J Hepatol. 2013; 59(3):415–417.
higher, although not signiﬁcantly, than those without
AKI. However, progression of AKI and mortality were
signiﬁcantly higher, whereas resolution of AKI was signiﬁcantly lower in AKI-1 patients with serum creatinine more
than 1.5 mg/dL compared with less than 1.5 mg/dL. Patients
from both studies whose serum creatinine rose by more
than 0.3 mg/dL but did not achieve a zenith of 1.5 mg/dL
had a good prognosis. Additionally, kidney parenchymal
disease that is slowly progressive is associated with a better
prognosis than type 2 HRS (3-month survival, 73% vs 15%)
and more favorable than kidney failure associated with volume depletion (46%) and infections (31%).13
Outpatient consultation of liver disease in the kidney
clinic is represented largely by nonalcoholic fatty liver disease (NAFLD), which dominates the clinical picture along
with HCV-induced disease. NAFLD is associated with
obesity, insulin resistance, and diabetes. The 50 -AMP activated protein kinase energy sensor undoubtedly plays a
pivotal role in both the kidney and liver disorders, with
relative adiponectin deﬁciency playing an instrumental
role. The dual dysfunction is contingent on an “interorgan
communication” among adipose, liver, and kidney tissues
as orchestrated by fetuin-A that inhibits insulin receptor
kinase in liver and skeletal muscle and reduces adiponectin expression. Low levels of adiponectin correspond to
increased hepatic ﬁbrosis and podocytopathy through a
reduction in 50 -AMP activated protein kinase stimulation.14 Kidney disease is often missed or ignored until
there is an elevation of serum creatinine, edema formation,
or the onset of proteinuria. Sometimes, there must be frank
cirrhosis and AKI to prompt a kidney consultation, which
is precisely why nephrologists must work proactively and
collaboratively in an engaged fashion with liver specialists.
Liver ﬁbrosis is easier to detect with the advent of the hepatic ﬁbroscan—hepatic ultrasonic elastography.15
This test correlates shear wave velocity with hepatic stiffness, ie, ﬁbrosis. Combined with hepatic biomarkers, this
noninvasive technique can obviate liver biopsy as it evaluates the presence of signiﬁcant ﬁbrosis fairly well and its
exclusion with a sensitivity of 100% and speciﬁcity of
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91%. However, it performs less well for intermediate stages
of ﬁbrosis and cannot be adequately performed in obese patients or those with ascites. In these cases, magnetic resonance imaging elastography that has a technical success
rate of 96% (vs 92% for shear wave elastography) may be
performed, but this cross-validated technique is technically
more demanding.16
In patients with advanced liver disease, the serum creatinine is subject to multiple inﬂuences and may not reﬂect the
true glomerular ﬁltration rate (GFR). Among these inﬂuences are an impairment of protein intake and sarcopenia
from chronic illness. Although a 24-hour urine creatinine
collection may mirror the true GFR better than any serum
creatinine-estimating equation, proximal tubular secretion
of creatinine still muddies the plasma water, which may be
further obfuscated by elevated bilirubin levels (depending
on the creatinine measurement technique). Cystatin Cbased equations are rarely used to interpret the GFR in liver
patients despite their superiority in this particular
context.17 Others advocate for the use of the Modiﬁcation
of Diet in Renal Disease (MDRD) Equation 6 in liver disease.18 Recall that in Equation 6, GFR is a function of age,
creatinine, race, and sex as with the MDRD Equation 4
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plus albumin and blood urea nitrogen. Hypoalbuminemia
and elevated blood urea nitrogen serve to lower GFR.
Although a Danish group strongly advised against using
MDRD equations for GFR estimation in solid organ transplant recipients, Shafﬁ and colleagues19 concluded that
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) and MDRD equations were the most suitable
for GFR estimation in these patients. More recently, another
group demonstrated that the most accurate equation by
Bland-Altman analysis was a creatinine and 51Cr-EDTAbased equation that proved superior to 2 creatinine-based
and three cystatin C-based formulas.20
HCV-associated kidney disease is most frequently associated with histologically evident membranoproliferative
glomerulonephritis but may manifest much less commonly
as a membranous nephropathy. Mixed, essential cryoglobulinemic vasculitis that involves humoral immunity
with participant B and T cells but not the virus itself21
may generate a kidney failure-hypertension syndrome
without glomerulitis.22 Now, HCV is more curable than
previously and to a far greater extent. The nucleoside
analogue, ribavirin, added to alpha-interferon (IFN) therapy substantially improved virologic remission rates

Hepato-nephrologist busily at work. Original artwork by Thomas Mattix, Mattix Illustrations, Columbus, Ohio.
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compared with interferon alone. Yet anti-HCV treatment
with these agents was shunned by the liver- and kidneytreating communities at relatively well-preserved levels of
GFR, attributable to fears of inducing hemolytic anemia
from ribavirin. This denial of treatment occurred despite
successful pegylated interferon plus ribavirin therapy
with plasma trough level monitoring in patients with
GFRs in the range of 10 to 65 mL/min and in dialysis patients who required high dosages of erythropoietin.23,24
Treatment of HCV today is at a tipping point and the therapeutic lever that balances costs of treatment against newer
NS5B RNA polymerase inhibitors pivots on a fulcrum of
dollars.25 In 2013, sofosbuvir was Food and Drug Administration approved. It can be combined with ribavirin for
treatment of HCV genotypes 2 and 3. For the more vexing
genotypes 1 and 4, pegylated IFN is added. In 2014, nonIFN-based therapy of genotype 1 HCV was approved as
the combination of sofosbuvir and ledipasvir, an NS5A inhibitor. Although the efﬁcacy of these newer agents is not
in dispute, their associated costs have provided a reverberating debate. The volume of this ﬁerce dialog may soon subside with the introduction of several competitor agents in
the near term.26 Overall, the scourge of HCV could be substantially contained pending worldwide availability and
distribution of these agents. Let’s hope so, as this will help
the rates of hepatocellular carcinoma and cirrhosis from
HCV to fall along with the accompanying burden of CKD.
The implications for improvement in worldwide health
would be incredible, particularly in countries where HCV
is highly endemic such as Egypt, multiple other African
countries, and Pakistan.
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